Rankings
▼
Calendar
▼
OKUR Q1 2023 Earnings Report — OnKure Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
OnKure Therapeutics, Inc.
OKUR
Q1 2023 Earnings
Reported March 31, 2023
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
Q1 2023
Q4 2022
Q1 2022
QoQ Change
YoY Change
Revenue
$0
—
—
—
—
Op. Income
-$9M
—
—
—
—
EPS (Diluted)
$-0.65
—
—
—
—
Free Cash Flow
-$5M
—
—
—
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$8M
Selling & Marketing
$0
General & Administrative
$1M
SG&A Expenses
$1M
Other Expenses
$0
Operating Expenses
$9M
Cost & Expenses
$9M
OPERATING INCOME
-$9M
Interest Income
$73.0K
Interest Expense
$0
Other Income/Expenses
$73.0K
INCOME BEFORE TAX
-$9M
Income Tax Expense
$0
Net Income from Continuing Ops
-$9M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$9M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$9M
D&A
$128.0K
EBIT
-$9M
EBITDA
-$9M
EPS
-$1
EPS Diluted
-$1
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$9M
Depreciation & Amortization
$128.0K
Stock-Based Compensation
$15.0K
Deferred Income Tax
$0
Other Non-Cash Items
-$1.0K
Change in Working Capital
$4M
OPERATING CASH FLOW
-$5M
Capital Expenditure
-$11.0K
Acquisitions (Net)
$0
Purchases of Investments
$0
Sales/Maturities of Investments
$0
Other Investing Activities
$0
NET CASH FROM INVESTING
-$11.0K
Net Debt Issuance
$0
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
-$716.0K
NET CASH FROM FINANCING
$53M
FREE CASH FLOW
-$5M
Net Change in Cash
$49M
marketcaparena.com
← FY 2023
OKUR Overview
Q2 2023 →